Abstract
In order to assess the efficacy of modern antiepileptic drug (AED) therapy, we collected data from 517 consecutive adult outpatients referred to our centre between March and August 2011. In total, 211 patients (40.8%) were treated with monotherapy, 208 patients (40.2%) with a combination of two AEDs, and for the remaining patients (n=98; 19%) more than two AEDs were combined. The most common AEDs were valproate, lamotrigine, carbamazepine, and levetiracetam. Of the recent AEDs, levetiracetamwas the leading drug with regards to drug combinations. Freedom of seizures for more than one year was achieved in 291 patients (56.3%). Under monotherapy, 168 patients (32.5% of all patients; 79.6% of patients with monotherapy) became seizure-free. Seizure-freedom with two AEDs was achieved in 103 patients (19.9% of all patients; 49.5% of patients with two AEDs) and in 20 patients with three AEDs (3.9% of all patients; 25.3% of patients with three AEDs). We conclude from this cross-sectional survey in a large patient group that combinations may still lead to treatment success in a considerable proportion of patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57: 1–13.
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010; 51: 676–685.
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010; 51: 7–26.
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia 2012; 53: 512–520.
Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary on the Tenth Eilat Conference (Eilat X). Epilepsy Res 2010; 92: 89–124.
Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43: 535–538.
Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–479.
Brodie MJ, Overstall PW, Giorgi L. Multicentre, doubleblind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81–87.
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, & Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408.
Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382–389.
Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282–1288.
Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–460.
Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–76.
Deckers CL, Hekster YA, Keyser A, van Lier HJ, Meinardi H, Renier WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387–1394.
Diener HC, Putzki N, Berlit P, et al. Leitlinien für Diagnostik und Therapie in der Neurologie. 4th ed. Stuttgart; New York: Georg Thieme, 2008.
Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005; 65: 593–595.
French JA, Faught E. Rational polytherapy. Epilepsia 2009; 50: 63–68.
Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002; 58: S9–S20.
Guerreiro MM, Vigonius U, Pohlmann H, et al. Adouble-blind controlled, clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205–213.
Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000a; 9: 464–468.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000b; 342: 314–319.
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069–1077.
Larkin JG, McLellan A, Munday A, Sutherland M, Butler E, Brodie MJ. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. Br J Clin Pharmacol 1989; 27: 313–322.
Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62: 375–381.
Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165–175.
Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000; 356: 285–290.
Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149–155.
Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981; 22: 1–10.
Sake J-K, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010; 24: 1055–1068.
Sheth RD, Harden CL. Screening for bone health in epilepsy. Epilepsia 2007; 48: 39–41.
Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. Br Med J 1977; 1: 1635–1637.
Staack AM, Jürges U, Kurth C, Winkler C, Steinhoff BJ. Differential impact of monotherapies with carbamazepine, oxcarbazepine and lamotrigine on clinically relevant laboratory values. Z Epileptol 2007; 20: 135–142.
Steiner TJ, Dellaportas CL, Findley LJ, et al. Lamotrigine monotherpay in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–607.
Steinhoff BJ, Ueberall MA, Siemes H, et al. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure 2005; 14: 597–605.
Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res 2012; 98: 194–198.
Szaflarski JP, Rackley AY, Lindsell CJ, Szaflarski M, Yates SL. Seizure control in patients with epilepsy: the physician vs. medication factors. BMC Health Serv Res 2008; 18: 264.
Villanueva V, López-Gomáriz E, López-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice: results of Spanish cohort analysis RELACOVA. Epilepsy Behav 2012; 23: 298–304.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Steinhoff, B.J., Staack, A.M. & Wisniewski, I. Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disord. 14, 379–387 (2012). https://doi.org/10.1684/epd.2012.0544
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0544